Clinical trials: IBS (Irritable Bowel Syndrome)
IBS - Irritable Bowel Syndrome
Sex Differences in Effectiveness of CBT on IBS Project 3
Cognitive Behavioral Therapy (CBT) is the most well researched and most effective treatment for IBS targeting the brain-gut-microbiome (BGM) axis, and preliminary data show that this therapeutic effect is associated with a…
- Trial name
- U54_P3_CBT (NCT05155631)
- Testing
- COGNITIVE BEHAVIORAL THERAPY
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of California, Los Angeles
IBS - Irritable Bowel Syndrome
Zemedy Application for Irritable Bowel Syndrome
The purpose of the study is investigate the effectiveness of Zemedy, a mobile application that enables the digital delivery of a CBT program to people with IBS.
- Trial name
- NCT04723056
- Testing
- Use of Zemedy Application
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Stanford University
IBS - Irritable Bowel Syndrome
Irritable Bowel Syndrome and Control Volunteers: Diet Challenge
The purpose of this study is to study the relationship between the bile acids, short chain fatty acids and bacteria within the intestines.
- Trial name
- NCT03983434
- Testing
- Inulin
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Indiana University
Irritable Bowel Syndrome With Diarrhea (IBS-D)
A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
- Trial name
- NCT03931785
- Testing
- MD-7246
- Where
- 80 sites in United States
- Volunteers
- 515 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome With Constipation (IBS-C)
A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C
A Single-Dose, Open-Label, Extension Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation
- Trial name
- NCT02493036
- Testing
- SYN-010
- Where
- 11 sites in United States
- Volunteers
- 54 people
- Sponsor
- Theriva Biologics, Inc.
Irritable Bowel Syndrome With Constipation (IBS-C)
A Study of the Effect of SYN-010 on Subjects With IBS-C
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Dose Study of the Effect of Two Dosage Strengths of SYN-010 Compared with Placebo on Breath Methane Production in Breath Methane-Positive Subjects with…
- Trial name
- NCT02495623
- Testing
- SYN-010 21 mg, SYN-010 42 mg
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Theriva Biologics, Inc.
Irritable Bowel Syndrome (IBS)
Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
This is a double-blind, placebo-controlled, randomised crossover study to investigate the efficacy and safety of GW876008
- Trial name
- NCT00421707
- Testing
- GW876008
- Where
- 23 sites in United States, Canada
- Volunteers
- 133 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome (IBS), Functional Abdominal Pain
Peer Mentorship: An Intervention To Promote Effective Pain Self-Management In Adolescents
This protocol matches child subjects with peer mentors of similar age who have learned to function successfully with a chronic pain disorder.
- Conditions
- Irritable Bowel Syndrome (IBS), Functional Abdominal Pain, Fibromyalgia, Complex Regional Pain Syndrome (CRPS)
- Trial name
- NCT01118988
- Testing
- Mentorship
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, Los Angeles
Irritable Bowel Syndrome With Constipation (IBS-C)
A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
This clinical trial is an international, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial comparing one dose of linaclotide to placebo.
- Trial name
- D5630C00001 (NCT01880424)
- Testing
- Linaclotide
- Where
- 82 sites in United States, Australia and 3 more
- Volunteers
- 1,722 people
- Sponsor
- AstraZeneca